Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / TNFSF8



This biomarker is also known as:
  • CD30LG,
  • tumor necrosis factor ligand superfamily member 8,
  • CD153 antigen,
  • CD30 antigen ligand,
  • CD30L,
  • CD30-L,
  • CD30 ligand,
  • CD153,
  • tumor necrosis factor (ligand) superfamily, member 8,


TNFSF8, also known as CD30 ligand, is a cytokine belonging to the tumor necrosis factor (TNF) ligand family. TNFSF8 binds to TNFRSF8/CD30, a cell surface antigen and a marker for Hodgkin lymphoma and related hematologic malignancies. TNFSF8 has been shown to induce proliferation of T-cells. It also enhances cell proliferation of some lymphoma cell lines, and induces cell death and reduces cell proliferation of other lymphoma cell lines. There are two different isoforms encoded by two transcript variants.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Curated


TNFSF8 variants may be involved in the etiology of lung cancer.

Performance Comment

TNFSF8 is a member of the TNF ligand superfamily, which stimulates T-cell growth. Up-regulation of this protein correlates with proliferation in hematological malignancies. Further studies have shown possible involvement in susceptibility to lung cancer. TNFSF8 is also a member of a 12 protein panel that can discriminate NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.


Mutation Statistics

Gene Name: TNFSF8
UniProt Accession #: P32971
Mutated Sites Count: 44
Associated Pubmed ID Count 10
CancerDO Count 21
Affected Protein Function Sites Count: 5

View in BioMuta